Delving into the Latest Updates on Vilaprisan with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Bayer-sPRM, S-PRAnt, S-PRM

+ [5]

Target

PR

Mechanism

PR antagonists(Progesterone receptor antagonists)

Therapeutic Areas

NeoplasmsUrogenital Diseases

Active Indication-

Inactive Indication

EndometriosisLeiomyomaMenorrhagia+ [1]

Originator Organization

Bayer AG

Active Organization-

Inactive Organization

Bayer AG

Bayer Healthcare Co., Ltd.Bayer Weimar GmbH und Co. KG

+ [1]

Drug Highest PhaseDiscontinuedPhase 3

First Approval Date-

RegulationSpecial Review Project (CN)

Login to view timeline

Structure/Sequence

Molecular FormulaC27H29F5O4S

InChIKeyJUFWQQVHQFDUOD-ANRPBIDPSA-N

CAS Registry1262108-14-4

The primary objective of this study is to show superiority of vilaprisan in the treatment of heavy menstrual bleeding (HMB) in subjects with uterine fibroids compared to placebo.The secondary objectives of this study are to additionally evaluate the efficacy and safety of vilaprisan in subjects with uterine fibroids.

Start Date27 Oct 2018

Sponsor / Collaborator

Bayer AG

NCT03573336

/ TerminatedPhase 2

A Randomized, Double-blind, Parallel-group, Multicenter Phase 2b Study to Assess the Efficacy and Safety of Two Different Doses of Vilaprisan (BAY1002670) Versus Placebo in Women With Symptomatic Endometriosis

The primary objective of this study was to assess the efficacy and safety of two doses of vilaprisan compared to placebo in women with symptomatic endometriosis.
The secondary objective of this study was to evaluate the safety and tolerability of two different doses of vilaprisan in women with symptomatic endometriosis.
With the implementation of protocol version 4.0 dated 11-Dec-2018, no new subjects were enrolled. The objectives above cannot be reached as only limited data is available from subjects recruited before the temporary pause.

Start Date04 Jul 2018

Sponsor / Collaborator

Bayer AG

100 Clinical Results associated with Vilaprisan

Login to view more data

100 Translational Medicine associated with Vilaprisan

Login to view more data

100 Patents (Medical) associated with Vilaprisan

Login to view more data

363

Literatures (Medical) associated with Vilaprisan

01 Feb 2025·Poultry Science

Safety study of fluralaner solution on poultry red mite: A clinical study screening of the optimal dose and focusing on hepatic and renal parameters

Article

Author: Xu, Fei ; Jiang, Lin ; Li, Xiubo ; Wang, Xinyu ; Sun, Tingting ; Wu, Hao ; Liu, Jing

The poultry red mite (PRM), Dermanyssus gallinae, a significant ectoparasite causing diseases in poultry, is globally prevalent and necessitates effective control strategies. There are restrictions on the use of acaricides in poultry across several nations due to worries about medication residues. Consequently, finding safe and efficient treatments for PRM is imperative. Fluralaner solution has emerged as a potential therapeutic agent, distinguished by its rapid onset, enduring efficacy, and lack of a withdrawal period for egg production. To ascertain the optimal dosage and therapeutic efficacy of fluralaner solution in PRM treatment, this study evaluated blood biochemical parameters and mite populations across various treatment groups. A cohort of 500 laying hens was randomly assigned to one of five treatment groups, each comprising 100 individuals:high-dose group (0.1 ml/kg-bw, group 4 ×, coop 1), medium-dose group (0.05 ml/kg-bw, group 2 ×, coop 5), low-dose group (0.025 ml/kg-bw, group 1 ×, coop 2), drug-control group (Intervet Productions, 0.05 ml/kg-bw recommended dose, coop 3) and blank control group (coop 4). Hens received their respective dosages of the fluralaner solution via oral administration on Days 0 (D0) and 7 (D7) of the experimental period. Over the study's ninety days, blood biochemical markers and mite counts in each coop were measured to evaluate the drug's safety, effectiveness, and ideal dosage. Data analysis was performed utilizing SPSS software. The study findings indicated that, for effective PRM infestation treatment, a dosage of 0.5 mg fluralaner per kilogram of body weight (equivalent to 0.05 ml) administered daily, followed by a subsequent dose post a 7-day interval, is recommended. Additionally, clinical observations coupled with blood biochemical assessments confirmed the safety of fluralaner across the three tested dosage levels in hens.

01 Feb 2025·Life Sciences

Progesterone signaling in uterine fibroids: Molecular mechanisms and therapeutic opportunities

Review

Author: Segars, James H ; Macri, Valeria I ; Ploumaki, Ioanna ; Islam, Md Soriful

Progesterone (P4) is a vital female sex hormone involved in various physiological processes, including the maintenance of the endometrium, mammary gland development, and bone health. Beyond its reproductive roles, P4 is implicated in the pathogenesis of hormone-dependent conditions like uterine fibroids, the most common benign tumors in women, which can severely affect quality of life and fertility. Traditionally, estrogen was considered the primary driver of fibroid growth, but recent research highlights the significant role of P4 in fibroid growth. P4 interacts with progesterone receptors (PRs) and non-genomic membrane receptors (mPRs and PGRMCs) to activate signaling pathways that enhance tumor growth and survival. P4 promotes vascular changes that improve the blood supply to fibroids and modifies the extracellular matrix, a key component of fibroid structure. This understanding has led to the investigation of selective progesterone receptor modulators (SPRMs) as potential therapies for fibroids. Clinical trials have demonstrated the effectiveness of SPRMs like mifepristone, asoprisnil, and ulipristal acetate in reducing fibroid size and symptoms, though concerns about safety, particularly with long-term use, remain. Newer SPRMs, such as vilaprisan, show promise, but further research is necessary to assess the long-term safety and effectiveness. This review discusses the mechanisms by which progesterone contributes to fibroid growth and examines clinical effectiveness of SPRMs as potential treatments for uterine fibroids.

28 Jan 2025·International Journal of Phytoremediation

Green synthesis of ZnO and Ni-doped ZnO from okra stalks for the photocatalytic degradation of Procion Red MX-5B

Article

Author: Orak, Ceren ; Biçer, Emre ; Horoz, Sabit

This study investigates the photocatalytic degradation of Procion Red MX-5B (PRM) using ZnO and Ni-doped ZnO catalysts derived from okra stalks through a green synthesis method. Various parameters, including hydrogen peroxide concentration (HPC), catalyst amount, nickel (Ni) doping amount, initial PRM concentration, and pH, are systematically studied to assess their impact on PRM degradation efficiency. The results reveal that both ZnO and Ni-doped ZnO catalysts exhibit promising photocatalytic activity, with the highest PRM degradation efficiency achieved at the following reaction conditions: 6 mM of HPC, 40 mg of Ni(7%):ZnO catalyst, 10 ppm initial PRM concentration, and pH = 6. Under these conditions, the Ni-doped ZnO catalyst demonstrated a degradation efficiency of 98.08% compared to 82.99% for the ZnO catalyst. The study highlights the potential of these catalysts for efficient organic pollutant removal and provides valuable insights into the factors influencing their photocatalytic performance.

100 Deals associated with Vilaprisan

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D11181	Vilaprisan	-	DB11971

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Uterine Fibroids	Phase 3	CZ	Bayer AG	30 Jun 2017
Uterine Fibroids	Phase 3	RU	Bayer AG	30 Jun 2017
Uterine Fibroids	Phase 3	TH	Bayer AG	30 Jun 2017
Uterine Fibroids	Phase 3	TR	Bayer AG	30 Jun 2017
Uterine Fibroids	Phase 3	TR	Bayer AG	30 Jun 2017
Uterine Fibroids	Phase 3	CZ	Bayer AG	30 Jun 2017
Uterine Fibroids	Phase 3	RU	Bayer AG	30 Jun 2017
Uterine Fibroids	Phase 3	ZA	Bayer AG	30 Jun 2017
Uterine Fibroids	Phase 3	TH	Bayer AG	30 Jun 2017
Uterine Fibroids	Phase 3	ZA	Bayer AG	30 Jun 2017

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ADA2023	Not Applicable	-	8	PRM A 3 mg/kg	hpfaxyrtdg(udntutvkzd) = fhtxkcifxr tsrimmoaym (upphbgmxmc )	-	20 Jun 2023
				PRM A 10 mg/kg	hpfaxyrtdg(udntutvkzd) = ydngygfzqj tsrimmoaym (upphbgmxmc )
NCT03400943 (CTgov)	Phase 3	Leiomyoma	93	Placebo+Vilaprisan (BAY1002670) (Vilaprisan (A1))	xcmbpbbscr(lubteokegv) = emmzmpejrr qixwfylbqf (xduskbbxco, ryntgeaowx - ctqslihkil) View more	-	11 Jun 2021
				Vilaprisan (BAY1002670) (Vilaprisan (A2))	xcmbpbbscr(lubteokegv) = ivhwcytdqz qixwfylbqf (xduskbbxco, kwcvunrdae - lxhddlwlve) View more
NCT03400956 (CTgov)	Phase 3	Uterine Fibroids	103	Vilaprisan (BAY1002670) (Vilaprisan (A1))	pkgzvfcmzw(pxhmublwqv) = ruvxdpnwkd tthvohlghy (uqiisfxugh, bcdymnpmcm - wzcaicivsq) View more	-	30 Apr 2021
				Placebo+Vilaprisan (BAY1002670) (Placebo+Vilaprisan (B1))	pkgzvfcmzw(pxhmublwqv) = evvqasbzsx tthvohlghy (uqiisfxugh, jdrhsafzqp - pjnpgafejv) View more
NCT03573336 (VILLENDO, CTgov)	Phase 2	Endometriosis	8	Vilaprisan (BAY1002670) (Vilaprisan (BAY1002670) 2 mg)	qsutlavcgd(cmmlrpplwt) = qyyypbtjuv xwpmemafra (peodyinhvs, gjdqlxqfqc - wbktfpeonm) View more	-	22 Jan 2021
				Vilaprisan (BAY1002670) (Vilaprisan (BAY1002670) 4 mg)	qsutlavcgd(cmmlrpplwt) = eoknhidfkj xwpmemafra (peodyinhvs, rdpiatiaoy - plsgzxdgpt) View more
NCT02465814 (ASTEROID 2, Pubmed \| Eur J Obstet Gynecol Reprod Biol)	Phase 2	Uterine Fibroids	155	Vilaprisan	bjmlcaiwlq(ranpjiasdf) = npviplzdka panydmyqax (ttnnobzirj ) View more	Positive	31 May 2020
				Ulipristal acetate	hmaaaijyeh(wrkkcteado) = hcutxndlyi horeexmobi (dlfbzmgenj ) View more